Greed and intention cloud launch of generic EpiPen
A discounted version of the auto-injector hits stores this week. The manufacturer tries to sympathize with ‘escalating pharma prices,’ but consumers label it a ‘PR stunt.’
Time hasn’t healed the price gouging pain that consumers felt this summer when Mylan Pharmaceutical’s hiked the price of its EpiPen 2-Pak.
The company and CEO Heather Bresch were blasted for raising the price to $600. A fiery hearing on Capitol Hill left the company reeling. Mylan agreed to pay the federal government $465 million for falsely classifying EpiPens and overcharging Medicaid.
On Friday, Mylan issued a press release about the availability of the new discounted auto-injector, used to counteract severe allergic reactions. It introduced a new website for consumers to access savings.
The statement also had Bresch’s spin on the company’s concern about broad pharmaceutical price-gouging:
Become a Ragan Insider member to read this article and all other archived content.
Sign up today
Already a member? Log in here.
Learn more about Ragan Insider.
